-
Tracing the Shift in Payer Evidence Expectations: A Review of AMCP Format Updates (2016-2024)
Sep 9, 2025, 16:22 PM -
Health Economic Evaluation Model for Prostate Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
Sep 9, 2025, 16:22 PM -
Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Ribociclib With Endocrine Therapy for Treatment With Premenopausal Women With HR Positive HER2 Negative Early Breast Cancer in the UK
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Evaluation of RSVpreF Vaccine for Preventing RSV Among Older Adults With High Risk Under Taiwan National Vaccination Program
Sep 9, 2025, 16:22 PM -
Is NICE’s Proportionate Approach Achieving Its Objective: Analysis of Time to Access for Cost Comparison vs. Single Technology Appraisal
Sep 9, 2025, 16:22 PM -
Cardiovascular Disease Risk-Reducing Strategies in Qatari Diabetes Patients: A Cost-Effectiveness Study
Sep 9, 2025, 16:22 PM -
Budget Impact of Azathioprine Metabolite Monitoring in Crohn’s Disease in Algeria
Sep 9, 2025, 16:22 PM -
Cost of First-Line Treatment of Hepatocellular Carcinoma With the Immune Checkpoint Inhibitor-Based Regimens STRIDE and Atezolizumab Plus Bevacizumab in Brazil
Sep 9, 2025, 16:22 PM -
The Socioeconomic Value of Adult Respiratory Immunization Programs in Spain: How Much Can We Gain From Expanding Prevention Efforts?
Sep 9, 2025, 16:22 PM -
LLM Engineering in HEOR: Approaches to Improving Accuracy in Clinical Data Extraction
Sep 9, 2025, 16:22 PM -
Transforming Pediatric Type 1 Diabetes Care in Bulgaria Through Structured Patient Journey Analysis
Sep 9, 2025, 16:22 PM -
Ensuring Patient Inclusion When Baseline Is Missing: Utilizing Constrained Longitudinal Data Analysis (cLDA) for Patient-Reported Outcomes (PROs)
Sep 9, 2025, 16:22 PM -
NICE and CDA Assessment of Artificial Intelligence-Enabled Health Technologies: Analysis and Insights
Sep 9, 2025, 16:22 PM -
Pertussis Vaccination and Test Rates in Germany by Asthma-COPD Comorbidity Status: A Healthcare Claims Data Analysis in Germany
Sep 9, 2025, 16:22 PM -
Navigating HTA and Innovation: Oncologists’ Perspectives on Access to Cancer Therapies in Bulgaria
Sep 9, 2025, 16:22 PM -
An Economic Evaluation of Risankizumab vs. Adalimumab in Moderate to Severe Plaque Psoriasis Adult Patients in Egypt
Sep 9, 2025, 16:22 PM -
An Evaluation of the Cost of Treatment for Low-Back Pain Among Patients Attending Public Healthcare Facilities in Nigeria
Sep 9, 2025, 16:22 PM -
The IMPACT Framework: A Value Assessment Framework for Holistic Health Technology Assessment
Sep 9, 2025, 16:22 PM -
From Evidence Gaps to Launch Delays: A Review of Health Technology Assessment Critiques and Health Economics and Outcomes Research Strategy Readiness
Sep 9, 2025, 16:22 PM
